Business Standard

Wednesday, January 08, 2025 | 11:46 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Lupin Q1 net plunges 59% to Rs 358 cr on price erosion in US

Revenue for the quarter too declined 13.4% on a year-on-year basis to Rs 3,869 crore

An employee of Lupin Limited works at a reception at their headquarters in Mumbai
Premium

An employee of Lupin Limited works at a reception at their headquarters in Mumbai

Aneesh Phadnis Mumbai
Price erosion of key anti diabetes drug Glumetza in the US and muted sales growth in the domestic market due to good and service tax implementation in India resulted in 59 per cent fall in Lupin's profit in first quarter of FY18.

Net profit for the quarter under review of FY18 was Rs 358 crore as against Rs 882 crore in the same period a year ago. Revenue for the quarter too declined 13.4 per cent on a year-on-year basis to Rs 3,869 crore. Along with price erosion and GST disruption, revenue was also impacted due to the strengthening of rupee and headwinds in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in